Androgen deprivation therapy

Nima Sharifi

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Androgen deprivation therapy (ADT) is the upfront systemic therapy for advanced prostate cancer. ADT is administered medically or through surgical castration, and it suppresses serum testosterone levels. Furthermore, ADT may be given alone or in combination with an androgen receptor antagonist. Adverse effects include hot flashes, sexual dysfunction, increased risk of fracture, metabolic syndrome and increased risk of cardiovascular events. The timing of administration of early versus late ADT is still contentious and under active debate. Intermittent ADT may be an alternative to continuous testosterone depletion; although intermittent therapy decreases adverse effects, the comparative efficacy of each is still under active study. The study of germline genetic determinants in response to ADT is in its early phase. However, these studies have the potential to allow for patient selection for the type and timing of ADT.

Original languageEnglish (US)
Title of host publicationDrug Management of Prostate Cancer
PublisherSpringer New York
Pages101-107
Number of pages7
ISBN (Print)9781603278317
DOIs
StatePublished - 2010

Fingerprint

Androgens
Therapeutics
Testosterone
Androgen Receptor Antagonists
Hot Flashes
Castration
Patient Selection
Prostatic Neoplasms
Serum

Keywords

  • Androgen deprivation therapy
  • Androgens
  • Prostate cancer
  • Testosterone

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Sharifi, N. (2010). Androgen deprivation therapy. In Drug Management of Prostate Cancer (pp. 101-107). Springer New York. https://doi.org/10.1007/978-1-60327-829-4_9

Androgen deprivation therapy. / Sharifi, Nima.

Drug Management of Prostate Cancer. Springer New York, 2010. p. 101-107.

Research output: Chapter in Book/Report/Conference proceedingChapter

Sharifi, N 2010, Androgen deprivation therapy. in Drug Management of Prostate Cancer. Springer New York, pp. 101-107. https://doi.org/10.1007/978-1-60327-829-4_9
Sharifi N. Androgen deprivation therapy. In Drug Management of Prostate Cancer. Springer New York. 2010. p. 101-107 https://doi.org/10.1007/978-1-60327-829-4_9
Sharifi, Nima. / Androgen deprivation therapy. Drug Management of Prostate Cancer. Springer New York, 2010. pp. 101-107
@inbook{0ce81e8653554ca18d55b1242fb66b09,
title = "Androgen deprivation therapy",
abstract = "Androgen deprivation therapy (ADT) is the upfront systemic therapy for advanced prostate cancer. ADT is administered medically or through surgical castration, and it suppresses serum testosterone levels. Furthermore, ADT may be given alone or in combination with an androgen receptor antagonist. Adverse effects include hot flashes, sexual dysfunction, increased risk of fracture, metabolic syndrome and increased risk of cardiovascular events. The timing of administration of early versus late ADT is still contentious and under active debate. Intermittent ADT may be an alternative to continuous testosterone depletion; although intermittent therapy decreases adverse effects, the comparative efficacy of each is still under active study. The study of germline genetic determinants in response to ADT is in its early phase. However, these studies have the potential to allow for patient selection for the type and timing of ADT.",
keywords = "Androgen deprivation therapy, Androgens, Prostate cancer, Testosterone",
author = "Nima Sharifi",
year = "2010",
doi = "10.1007/978-1-60327-829-4_9",
language = "English (US)",
isbn = "9781603278317",
pages = "101--107",
booktitle = "Drug Management of Prostate Cancer",
publisher = "Springer New York",

}

TY - CHAP

T1 - Androgen deprivation therapy

AU - Sharifi, Nima

PY - 2010

Y1 - 2010

N2 - Androgen deprivation therapy (ADT) is the upfront systemic therapy for advanced prostate cancer. ADT is administered medically or through surgical castration, and it suppresses serum testosterone levels. Furthermore, ADT may be given alone or in combination with an androgen receptor antagonist. Adverse effects include hot flashes, sexual dysfunction, increased risk of fracture, metabolic syndrome and increased risk of cardiovascular events. The timing of administration of early versus late ADT is still contentious and under active debate. Intermittent ADT may be an alternative to continuous testosterone depletion; although intermittent therapy decreases adverse effects, the comparative efficacy of each is still under active study. The study of germline genetic determinants in response to ADT is in its early phase. However, these studies have the potential to allow for patient selection for the type and timing of ADT.

AB - Androgen deprivation therapy (ADT) is the upfront systemic therapy for advanced prostate cancer. ADT is administered medically or through surgical castration, and it suppresses serum testosterone levels. Furthermore, ADT may be given alone or in combination with an androgen receptor antagonist. Adverse effects include hot flashes, sexual dysfunction, increased risk of fracture, metabolic syndrome and increased risk of cardiovascular events. The timing of administration of early versus late ADT is still contentious and under active debate. Intermittent ADT may be an alternative to continuous testosterone depletion; although intermittent therapy decreases adverse effects, the comparative efficacy of each is still under active study. The study of germline genetic determinants in response to ADT is in its early phase. However, these studies have the potential to allow for patient selection for the type and timing of ADT.

KW - Androgen deprivation therapy

KW - Androgens

KW - Prostate cancer

KW - Testosterone

UR - http://www.scopus.com/inward/record.url?scp=84891390240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891390240&partnerID=8YFLogxK

U2 - 10.1007/978-1-60327-829-4_9

DO - 10.1007/978-1-60327-829-4_9

M3 - Chapter

SN - 9781603278317

SP - 101

EP - 107

BT - Drug Management of Prostate Cancer

PB - Springer New York

ER -